Hememics
1 known investors
Hememics develops FAST™, an immunoassay-based screening technology that detects multiple antibody targets in under one hour using custom user-supplied antibodies and antigens. The platform serves life sciences researchers and diagnostic laboratories as a faster and lower-cost alternative to traditional ELISA and Western blotting methods.
BiotechDeep TechMedical Devices
Investors · 1
In the news
- Hememics Biotech raises a $2 million seed round | Graphene-Infographene-info.com · 2023
- Hememics Biotechnologies Closes $2M Seed 2 Financingfinsmes.com · 2023
- Hememics Biotechnologies, Inc. Announces Successful Close in $2 Million Seed 2 Financing from TEDCO and Qualified Investors to Accelerate Growthprnewswire.com · 2023
- Hememics Biotechnologies - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Hememics Biotechnologies - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Hememics BARDA Funding for COVID-19 Rapid Test | M2D2 BlogM2D2blogs.uml.edu · 2020